President and CEO
Tim Scott serves as president and CEO and a member of the Board of Directors of Biocom California, the state’s leading life science advocate representing more than 1,800 members. Under his leadership, Biocom California drives public policy, creates access to capital development, builds an enviable network of industry leaders, introduces cutting-edge STEM education programs, and delivers value-driven purchasing programs. He oversees a team of 75 across offices in San Diego, Los Angeles, the San Francisco Bay Area, Sacramento, Washington, D.C. and Tokyo, collaborating with engaged boards to advance innovative benefits for members so they can advance medicines and medtech to address unmet medical needs.
With more than 20 years of entrepreneurial experience in biotech and pharmaceutical development, Mr. Scott previously led AustinPx, co-founded TEGA Therapeutics, and co-founded Pharmatek Laboratories, which was acquired by Catalent Pharma Solutions. He has also supported numerous spinouts from UC San Diego, including Zacharon Pharmaceuticals (acquired by BioMarin) and DTx (acquired by Novartis).
An active community leader, Mr. Scott serves on the boards of Avelas Biosciences and Rady Children’s Institute for Genomic Medicine. He is a trustee for the University of San Diego, the La Jolla Playhouse, Green Foundation for Earth Sciences at Scripps Institute of Oceanography and chairs the UC San Diego’s Dean’s Advisory Council for the Division of Biological Sciences.
Mr. Scott holds a B.A. in Biochemistry from UC San Diego and a J.D. from the University of San Diego. He is a member of the California Bar.